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uncertainty has contributed to the concern that apro-
tinin may be implicated in causing coronary graft
occlusion because of its powerful hemostatic
effects.6,7 This remains a controversial issue, however,
as numerous other trials have not identified a clinical
association between aprotinin use and graft occlusion
in coronary artery bypass surgery.8 In this study, we
have directly addressed in vitro the question whether
P ostoperative bleeding is an ever-present concern ofcardiac surgeons. Aprotinin (Trasylol; Bayer AG,
Leverkusen, Germany) is in widespread clinical use
for its ability to reduce blood loss and preserve platelet
function after cardiopulmonary bypass.1-5 The mecha-
nism of action of aprotinin on the platelet, however,
has remained uncertain since the first demonstration
of its hemostatic properties 12 years ago.1,2 This
Background: Despite aprotinin being in widespread clinical use to prevent
bleeding during cardiac surgery, there remains concern that such a powerful
hemostatic agent may also be prothrombotic, particularly in relation to coro-
nary vein graft occlusion. The major thrombin receptor on platelets, pro-
tease-activated receptor 1 (PAR1) requires proteolytic cleavage to transmit
activating signals. Here we have investigated the effect of aprotinin on
thrombin-induced PAR1 activation of platelets.
Methods and results: Proteolysis-dependent and -independent responses of
washed platelets were studied in vitro. Platelet aggregation induced by
trypsin was dependent on PAR1 (inhibited by the PAR1-specific antagonist
peptide, FLLRN) and was completely blocked by aprotinin at doses more
than 100 KIU/mL. Aggregation in response to thrombin, 1 nmol/L, was pre-
dominantly mediated through PAR1 and was inhibited 42.6% to 86.6% (P <
.05-.001) by pharmacologic doses of aprotinin (50-160 KIU/mL). Aprotinin
did not inhibit the nonproteolytic agonists collagen, epinephrine, adenosine
diphosphate, or phorbol 12-myristate 13-acetate. Furthermore, blockade of
the thrombin response by aprotinin did not prevent subsequent platelet
aggregation through collagen or epinephrine. Experiments with intraplatelet
Ca2+ fluxes, which provided an earlier measure of platelet activation, placed
the effect of aprotinin proximal to the PAR1 activation event. Since aprotinin
did not inhibit platelet responses to the nonproteolytic PAR1 agonist peptide,
SFLLRN, this implied that aprotinin acted by preventing PAR1 receptor
cleavage by thrombin.
Conclusions: Aprotinin inhibits thrombin-induced platelet activation by pre-
venting proteolysis of the PAR1 receptor. These findings argue against apro-
tinin being prothrombotic and suggest instead that aprotinin may have sig-
nificant antithrombotic effects. (J Thorac Cardiovasc Surg 2000;120:370-8)
Michael Poullis, FRCSa
Richard Manning, BScb
Mike Laffan, FRCPb
Dorian O. Haskard, FRCPc
Kenneth M. Taylor, FRCSa
R. Clive Landis, PhDc
THE ANTITHROMBOTIC EFFECT OF APROTININ: ACTIONS MEDIATED VIA THE PROTEASE-
ACTIVATED RECEPTOR 1
From the BHF Units of Cardiothoracic Surgerya and Cardiovascular
Medicine,b National Heart and Lung Institute, and the
Department of Haematology,c Hammersmith Hospital, Imperial
College School of Medicine, London, United Kingdom.
Supported by grants from the British Heart Foundation and Glaxo-
Wellcome PLC. 
Received for publication Feb 7, 2000; revisions requested April 11,
2000; revisions received May 4, 2000; accepted for publication
May 11, 2000.
Address for reprints: R. Clive Landis, PhD, BHF Cardiovascular
Medicine Unit, National Heart and Lung Institute, Imperial
College School of Medicine, Hammersmith Hospital, Du Cane
Road, London W12 0NN, United Kingdom (E-mail:
r.landis@ic.ac.uk).
Copyright © 2000 by The American Association for Thoracic
Surgery
0022-5223/2000 $12.00 + 0 12/1/108531
doi:10.1067/mtc.2000.108531
aprotinin can influence thrombin-induced platelet
activation.
Thrombin plays a central role in the hemostatic
response to cardiopulmonary bypass. Its generation in
response to the bypass circuit is of great concern to car-
diac surgeons and is associated with platelet dysfunc-
tion, excessive bleeding, and an increased incidence of
graft occlusion.9-12 The major thrombin receptor on
platelets is protease-activated receptor 1 (PAR1), a 7-
transmembrane receptor and member of the G pro-
tein–coupled superfamily of receptors.13 In common
with other G protein–coupled receptors, PAR1
responds to the binding of ligand by transducing a het-
erotrimeric G protein–coupled signal into the cell,
resulting in a Ca2+ flux and cellular activation.14
However, a unique feature of PAR1 and the 3 other
members of the PAR subfamily (PARs 1-4) is a require-
ment for proteolytic cleavage to generate the intracel-
lular signal.13,15 PAR1 activation by thrombin involves
initial binding to a hirudin-like domain (amino acids
53-64) of the receptor followed by proteolytic cleavage
between arginine-41 and serine-42.16 Cleavage of
PAR1 is via the serine protease activity of thrombin,
which may be mimicked at lower efficiency by other
unrelated serine proteases, such as trypsin. Proteolytic
cleavage unmasks a tethered ligand that interacts with
sequences corresponding to extracellular loop 2 of
PAR1, which in turn transduces heterotrimeric G pro-
tein–coupled intracellular responses.17 Many of the
native responses of thrombin can be reproduced by a
synthetic PAR1 agonist peptide, SFLLRN, which sim-
ulates the action of tethered ligand but critically does
not require proteolysis of the receptor.18,19
In addition to PAR1, platelets possess other thrombin
receptors, including PAR4 and glycoprotein Ib.20,21 The
PAR1 component of the platelet response to thrombin
or other PAR receptor agonists, such as SFLLRN or
trypsin, can be defined in vitro through the use of
PAR1-specific antagonistic peptides that competitively
block the binding of tethered ligand and thereby pre-
vent receptor activation.18,22 In the present article, we
have used such peptides to initially define in washed
platelets the PAR1 dependence of platelet activation in
response to thrombin and trypsin. We then tested the
hypothesis that aprotinin, as a broad-spectrum serine
protease inhibitor, might inhibit proteolytic signaling
via PAR1 and downstream platelet responses to the
agonists thrombin and trypsin. As a control, we com-
pared the effect of aprotinin on proteolysis-indepen-
dent pathways of platelet activation, including the use
of agonists SFLLRN, collagen, epinephrine, adenosine
diphosphate (ADP), and phorbol 12-myristate 13-
acetate (PMA). Our results show that aprotinin specifi-
cally inhibited thrombin and trypsin-induced platelet
activation by blocking the proteolytic cleavage of
PAR1.
Materials and methods
Reagents. Collagen, thrombin, trypsin, and aprotinin were
obtained from Sigma Diagnostics (Poole, United Kingdom).
The PAR1 agonist peptide, SFLLRN, was obtained from
Bachem UK Ltd (Saffron Walden, United Kingdom). PAR1
antagonist peptide, FLLRN, was synthesized by the
Advanced Biotechnology Centre (Imperial College School of
Medicine, London, United Kingdom).
Platelet preparation. Platelets were isolated from periph-
eral blood of normal healthy volunteers. In brief, blood was
collected into a prewarmed syringe containing sodium cit-
rate (105 mmol/L) in a 1:10 ratio and 2.0% dextrose by ante-
cubital venipuncture in the absence of a tourniquet.
Epoprostenol (prostacyclin) was added at a dose of 1 µmol/L
and platelet-rich plasma was decanted off after an initial spin
at 1100 rpm for 10 minutes. Platelet-rich plasma was recen-
trifuged at 2100 rpm for 12 minutes at room temperature and
the resulting pellet gently resuspended at 2 × 108 platelets
per milliliter in platelet buffer containing the following:
NaCl, 140 mmol/L; KCl, 5 mmol/L; MgCl2, 0.4 mmol/L;
NaHCO3, 25 mmol/L; D-glucose, 5 mmol/L; 0.2% bovine
serum albumin; and HEPES buffer, 20 mmol/L; pH 7.4.
Platelets were incubated at 37°C for 30 minutes before use and
were not activated according to the following criteria: (1)
platelet size less than 30 µL, assessed by a Sysmex counter
(Sysmex, Milton Keynes, United Kingdom), and (2) absence
of P-selectin surface expression, assessed by fluorescence-acti-
vated cell sorter analysis (Coulter Electronics Ltd, Bedford,
United Kingdom) with monoclonal anti–P-selectin antibody
AK-4 (Sigma) (fluorescent intensity of AK-4 staining relative
to isotype matched control antibody = 1.0, compared with 
> 7.0 after platelet activation). Absence of clotting factor con-
tamination was assessed by lack of detectable antithrombin III
(<0.01 U/mL), protein C (<0.01 U/mL), and protein S (<0.01
U/mL) in the platelet suspension.
Platelet aggregation. Platelet aggregation was studied with
the use of a Clandon Aggrecorder PA3220 device (Clandon YSI
Ltd, Farnborough, United Kingdom). In brief, 1 × 108 platelets
were resuspended in 450 µL platelet buffer adjusted to a 1.2-
mmol/L concentration of CaCl2 and containing a 100-µg/mL
concentration of fibrinogen before use. Aprotinin (50, 100, or
160 KIU/mL) or PAR1 antagonist peptides (500 µmol/L
FLLRN or 300 µmol/L MSRPACN) were added immediately
before platelet agonists at the following final concentrations:
thrombin, 1 nmol/L; trypsin, 1 µmol/L; collagen, 50 to 100
µg/mL; epinephrine, 2.5 to 10 µg/mL; ADP, 1 to 15 µmol/L;
PMA, 100 nmol/L; or SFLLRN, 100 µmol/L.
Intraplatelet Ca2+ levels. Platelets were loaded with fura-
2 AM (Molecular Probes Inc, Eugene, Ore) for 45 minutes at
37°C, as previously described.23 Fura-2–loaded platelets
were adjusted to 2 × 108 per milliliter. Measurements of intra-
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cellular calcium were obtained by measuring fura-2 fluores-
cence at 340-nm excitation and 510-nm emission with an LS
50 B spectrofluorometer (Perkin-Elmer, Beaconsfield, United
Kingdom). Aprotinin or PAR1 antagonist peptides were
added at the final concentrations indicated above until a
steady baseline reading was obtained. Platelet agonists were
added at the same concentrations as used in aggregometry,
after which fluorescence tracings were obtained. Intraplatelet
Ca2+ fluxes were determined by subtracting the baseline from
peak levels and calibrating to a known standard. Results are
expressed as the Ca2+ flux in nanomoles per liter.
Platelet microaggregation in whole blood. Platelet
microaggregation in whole blood was measured by counting
the number of single platelets remaining after aggregation.24
Then, 250 µL of peripheral blood was anticoagulated with
citrate, diluted in a 250-µL concentration of buffer in the
presence or absence of aprotinin at 160 KIU/mL, and single
platelet counts were performed with a Sysmex counter
(Sysmex) after the addition of thrombin (1 nmol/L), trypsin
(1 µmol/L), epinephrine (2.5 µmol/L), or ADP (2 µmol/L).
Platelets that had formed either microaggregates or macroag-
gregates are excluded from the single-platelet gate, and the
percentage of platelets that had aggregated is expressed rela-
tive to the platelet count before agonist addition.
Statistics. Platelet aggregation and intraplatelet Ca2+ flux
data were analyzed by a 1-way analysis of variance with a
Newman-Keuls post test (GraphPad Software Inc, San Diego,
Calif). 
Results
PAR1 dependence of platelet aggregation induced
by trypsin and thrombin. Trypsin has been shown to
possess agonist activity for both PAR1 and
PAR2,13,25,26 making it an ideal reagent with which to
examine PAR1-specific actions on platelets that only
express functional PAR1 and PAR4.15,27 Confirmation
of this fact is shown in Fig 1, A, which demonstrates
complete inhibition of trypsin-induced platelet aggre-
gation in washed platelets by the competitive PAR1
antagonist peptide, FLLRN. Aggregation induced by
trypsin was consistently slower than that induced with
thrombin, in keeping with the known lower affinity of
trypsin for PAR1.13,25 Aggregation was rapidly induced
by a 1-nmol/L dose of thrombin and was typically
inhibited 70% to 100% by PAR1 antagonist peptide
(Fig 1, B). Although PAR4 is not activated at this con-
centration of thrombin,27 residual aggregation may be
explained by the action of thrombin on non-PAR recep-
tors, such as glycoprotein Ib.21 The specificity of the
PAR1 antagonist peptide was confirmed by a lack of
effect on platelet aggregation induced by collagen, epi-
nephrine, and ADP (data not shown). Similar results
were obtained with a distinct PAR1 antagonist peptide,
MSRPACN, isolated from a random phage display
library22 (data not shown). These data therefore demon-
strate PAR1-specific platelet activation by trypsin and a
primary role for PAR1 in thrombin-induced platelet
aggregation.
Aprotinin inhibits platelet aggregation induced by
trypsin and thrombin. Fig 2, A and B, shows the
effect of aprotinin in increasing concentrations on
platelet aggregation induced by trypsin and thrombin.
Aprotinin completely inhibited trypsin-induced platelet
aggregation at 100 and 160 KIU/mL, concentrations
Fig 1. PAR1 dependence of trypsin-induced (A) and thrombin-induced platelet aggregation (B).
Washed platelets (1 × 108) were pretreated with the PAR1 antagonistic peptide, FLLRN (500
µmol/L), immediately before the addition of trypsin (1 µmol/L) or thrombin (1 nmol/L).
Aggregometry traces from an individual experiment are shown, representative of n = 4-6 for each
experimental condition.
A B
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that are relevant to cardiovascular surgery. Thrombin-
induced platelet aggregation was also significantly
inhibited by aprotinin, albeit incompletely (mean ± SD
inhibition from 6 donors, 42.6% ± 21.6% at 50
KIU/mL (P < .05), 61.0% ± 25.2% at 100 KIU/mL (P
< .05), and 86.6% ± 8.9% at 160 KIU/mL (P < .001)).
These results therefore demonstrated that aprotinin
strongly inhibited PAR1-mediated platelet aggregation
induced by both trypsin and thrombin.
The site of aprotinin action localizes to the proteo-
lytic cleavage event in PAR1 activation. The PAR1
agonist peptide, SFLLRN, triggers activation in the
absence of receptor cleavage by mimicking the tethered
ligand of PAR1. Fig 3 demonstrates that platelet aggre-
gation induced through SFLLRN was inhibited by the
competitive PAR1 antagonist peptide, FLLRN, but not
by aprotinin. The lack of complete inhibition with
antagonist is consistent with results in a previous
report18 (Fig 3, A). Aprotinin failed to inhibit platelet
aggregation with respect to SFLLRN, even when used
at high concentrations up to 400 KIU/mL (Fig 3, B). At
this concentration, aprotinin completely inhibited
thrombin-induced platelet aggregation. An inability to
block SFLLRN-induced aggregation localized the site
Fig 2. Aprotinin inhibits platelet aggregation induced by trypsin (A) and thrombin (B). Platelets were pretreated
with aprotinin at 50-, 100-, or 160-KIU/ml doses immediately before the addition of trypsin or thrombin.
Aggregometry traces from an individual experiment are shown, representative of n = 5-12 for each experimental
condition.
Fig 3. Aprotinin does not inhibit platelet aggregation induced by SFLLRN. Platelet aggregation was induced by
the PAR1 agonist peptide (PAR-1AP), SFLLRN (100 µmol/L), in the presence of antagonistic peptide, FLLRN
(125-500–µmol/L doses) (A), or aprotinin (50-160–KIU/mL doses) (B). Individual traces representative of n = 4
similar experiments are shown.
A B
BA
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of action of aprotinin proximal to the binding of teth-
ered ligand to the PAR1 receptor. These results strong-
ly suggested that blockade of trypsin and thrombin-
induced aggregation by aprotinin was due to inhibition
of receptor proteolysis, therefore preventing exposure
of the tethered ligand and signal transduction.
Aprotinin does not inhibit platelet aggregation
induced through collagen, epinephrine, ADP, or
PMA. The specificity of aprotinin action was next
examined with the use of the nonproteolytic agonists
collagen, epinephrine, ADP, and PMA (Fig 4, A-D).
Aprotinin did not block platelet aggregation in
Fig 4. Aprotinin does not inhibit proteolysis-independent pathways of platelet activation. Platelets were pretreated with
aprotinin, 160 KIU/mL, immediately before the addition of collagen (50 and 100 µg/mL) (A), epinephrine (Adrenaline)
(2.5 µmol/L) (B), ADP (2 µmol/L) (C), and PMA (100 nmol/L) (D). E and F depict aggregometry traces of platelets
pretreated with thrombin and aprotinin, before and after the addition of collagen (100 µg/mL) (E) or epinephrine (5
µmol/L) (F) marked by an arrow. Individual traces representative of n = 3-5 experiments are shown.
A B
C D
E F
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response to any of these stimuli and was therefore spe-
cific to the actions of PAR-dependent agonists such as
thrombin and trypsin. The lack of effect of aprotinin on
PMA-induced aggregation, a direct-acting protein
kinase C agonist, demonstrated that aprotinin had no
effect on protein kinase C or downstream signaling
pathways. These experiments also ruled out the possi-
bility that aprotinin was blocking a common distal
event in aggregation, such as the binding of fibrinogen
to glycoprotein IIb/IIIa. We next examined whether the
antithrombotic actions of aprotinin described in Fig 2,
B, could affect subsequent activation of platelets by
other agonists. In these experiments, platelets were first
treated with thrombin and aprotinin and then restimu-
lated with collagen or epinephrine. Fig 4, E and F,
demonstrates that inhibition of the thrombin pathway
by aprotinin does not prevent subsequent aggregation
from occurring in response to collagen or epinephrine.
The importance of this observation, particularly with
respect to collagen, which is likely to play an important
role in the formation of hemostatic plugs at sites that
are cut or approximated during cardiac surgery, is that
it reveals a simultaneous antithrombotic but not antihe-
mostatic property of aprotinin.
Aprotinin inhibits intraplatelet Ca2+ fluxes
induced by thrombin and trypsin. The mechanism of
action of aprotinin was further investigated by studying
intraplatelet Ca2+ mobilization in response to proteolyt-
ic and nonproteolytic platelet agonists. The Ca2+ trace
in Fig 5, A, illustrates a typical intraplatelet Ca2+ flux in
response to thrombin, occurring within 5 seconds of
thrombin addition. Fig 5, B, demonstrates that prior
addition of aprotinin completely abolished Ca2+ fluxes
in response to thrombin but had no effect on subsequent
activation through the non-PAR agonist epinephrine.
Furthermore, although aprotinin blocked Ca2+ fluxes to
thrombin, it had no effect on subsequent stimulation by
the proteolysis-independent PAR1 agonist peptide,
SFLLRN (Fig 5, C). These results demonstrate clearly
that the action of aprotinin was not directed at signaling
components of the PAR1 receptor complex but was
likely directed at the proteolytic cleavage event of
PAR1 activation. Fig 6, A to D, summarizes
intraplatelet Ca2+ flux data with the use of the platelet
agonists trypsin, thrombin, SFLLRN, and epinephrine,
respectively. Whereas aprotinin significantly reduced
peak intraplatelet Ca2+ levels in response to trypsin (P
= .008) and thrombin (P = .008), it had no significant
effect on stimulation by SFLLRN (P = .1) or epineph-
rine (P = .1).
Aprotinin specifically inhibits trypsin and throm-
bin-induced platelet aggregation in whole blood. To
extend the clinical relevance of our findings, which
used washed platelets, we repeated the basic observa-
tions in whole blood using microaggregation as a mea-
sure of platelet activation. Fig 7 demonstrates that
aprotinin inhibited formation of platelet microaggre-
gates induced by thrombin and trypsin but had no effect
on epinephrine- or ADP-induced aggregation.
Discussion
We have demonstrated that trypsin is a selective pro-
teolytic activator of PAR1 in washed platelets and that
aprotinin completely blocked this mechanism of platelet
activation. Activation by thrombin in a 1-nmol/L con-
centration has been previously shown to be primarily
mediated through PAR1,20,27 and this response was
Fig 5. Effect of aprotinin on intraplatelet Ca2+ fluxes induced
by thrombin, epinephrine (Adrenaline), or SFLLRN. Free
intracellular Ca2+ levels were measured in fura-2–loaded
platelets (1 × 108) by fluorimetry. A, Steady baseline reading
and intraplatelet Ca2+ flux after the addition of thrombin (1
nmol/L, arrow). B, Inhibition of thrombin-induced Ca2+ flux-
es by aprotinin (160 KIU/mL) but subsequent Ca2+ flux gen-
erated in response to epinephrine (5 µmol/L). C, Inhibition of
thrombin-induced Ca2+ fluxes by aprotinin and subsequent
flux in response to the PAR1 agonist peptide (PAR-1AP),
SFLLRN (100 µmol/L). Individual traces representative of n
= 3 experiments are shown.
A
B
C
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strongly inhibited by the synthetic PAR1 antagonist
peptide and aprotinin at concentrations relevant to car-
diac surgery. The absence of detectable clotting factors
in the washed platelet preparation argues against the
possibility that the effects of aprotinin were due to the
targeting of unrelated solution phase substrates. Effects
on platelet aggregation were mirrored by measurements
of intraplatelet Ca2+ fluxes, therefore indicating that
aprotinin inhibited a proximal event of platelet activa-
tion. Although aprotinin is likely to inhibit proteolytic
Fig 6. Effects of aprotinin and PAR1 antagonist peptide on Ca2+ fluxes in response to trypsin (A), thrombin (B),
SFLLRN (C), and epinephrine (adrenaline) (D) Ca2+ fluxes were calculated by subtracting the baseline from free
intraplatelet Ca2+ readings after addition of trypsin (1 µmol/L), thrombin (1 nmol/L), PAR-1 agonist peptide
(SFLLRN, 100 µmol/L), and epinephrine (Adrenaline, 5 µmol/L). The figure depicts mean Ca2+ fluxes ± SD in
response to agonist only (black column), agonist + aprotinin (160 KIU/mL, shaded column), and agonist + antag-
onist peptide, FLLRN (500 µmol/L, open column), from n = 4-6 experiments.
Fig 7. Specific inhibition by aprotinin of thrombin- and trypsin-induced microaggregation in whole blood. The
effect of aprotinin (160 KIU/mL) on microaggregation in whole blood was studied in response to the proteolysis-
dependent agonists thrombin (1 nmol/L) and trypsin (1 µmol/L) and proteolysis-independent agonists epinephrine
(Adrenaline, 2.5 µmol/L) and ADP (2 µmol/L). Results are expressed as the mean ± SD percentage microaggrega-
tion from n = 8-14 for each experimental condition.
A B
C D
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activation of PAR4, we did not test the higher concen-
trations of thrombin necessary to activate this pathway
and therefore cannot comment further on the effect of
aprotinin on PAR4 or other nonproteolytic pathways of
thrombin-induced aggregation. Additional relevance to
our findings has been suggested by the recent demon-
stration that PAR1 is the primary mediator of thrombin-
stimulated procoagulant activity.28 Taken together, our
data have shown that aprotinin exerts a significant
antithrombotic effect in washed platelets by inhibiting
platelet activation via PAR1.
The inhibitory mechanism of aprotinin was also spe-
cific, as platelet aggregation induced through non-PAR
agonists collagen, epinephrine, ADP, and PMA was not
blocked by aprotinin. This fact, together with Ca2+ flux
data, supports a receptor-specific mechanism of action
of aprotinin, upstream of PAR1 signaling. The clinical
relevance of these findings was further extended by
repeating basic observations in a study of microaggre-
gation in whole blood. Since aprotinin did not inhibit
PAR1 activation by the nonproteolytic agonist peptide,
SFLLRN, the implication is that aprotinin acted direct-
ly to prevent the serine protease-mediated cleavage of
the receptor and not on the PAR1 ligand binding site or
on the signaling components of the PAR1 receptor
complex.
Interestingly, blockade of thrombin-induced platelet
aggregation by aprotinin did not prevent subsequent
aggregation in response to collagen. These results are
consistent with the clinical observation that aprotinin
preserves platelet function during cardiopulmonary
bypass, presumably by inhibiting platelet activation
resulting from thrombin generation, yet does not pre-
vent formation of hemostatic plugs at wound and suture
sites where collagen is likely to be exposed.29-31 The
antithrombotic but not antihemostatic properties of
aprotinin we have described herein may have important
implications for the controversy surrounding the poten-
tial prothrombotic effect of aprotinin when given to
patients during coronary bypass surgery. Although the
weight of clinical evidence does not favor a detrimen-
tal association between aprotinin use and loss of graft
patency, surgeons’ concerns over this issue have not
fully been answered, as evidenced by the vigorous dis-
cussion prompted by the recent International
Multicenter Aprotinin Graft Patency Experience
(IMAGE) trial.7 The perception still exists that a pow-
erful hemostatic agent such as aprotinin may lead to an
increased risk of coronary vein graft occlusion.32 We
have always believed that this issue would be resolved
when the mechanism of action of aprotinin was better
understood. We have localized the in vitro mechanism
of action of aprotinin on platelets to the inhibition of
proteolysis of PAR1. Since PAR1 activation induced by
thrombin is specifically blocked by aprotinin, concerns
over a potential prothrombotic effect of aprotinin dur-
ing coronary surgery may be unfounded.
We thank Dr Sussan Nourshargh for assistance with the
intraplatelet calcium studies.
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